- 2024
-
Press releases - 05.09.2024
Ebola: a study in Guinea reveals persistent immunity five years after vaccination
Epidemics of Ebola virus disease occur periodically in several sub-Saharan African countries. Two vaccines have already received WHO prequalification against the Ebolavirus Zaire species. In a new study conducted in Guinea, scientists from VRI, Inserm and Université Paris-Est Créteil (U955 Institut Mondor de recherche biomédicale) have taken a further step in this direction. They have shown that the cellular immune response induced by three different vaccine strategies is maintained for up to five years after vaccination.
-
Press releases - 12.08.2024
Rapid rollout of smallpox vaccination reduces the risk of mpox
The ANRS DOXYVAC trial, promoted and funded by ANRS Emerging Infectious Diseases, and conducted by research teams from Inserm, AP-HP, Université Paris Cité and Sorbonne Université (France), shows that a rapid rollout of smallpox vaccination with MVA-BN (Modified vaccine Ankara) among HIV-positive men who have sex with men significantly reduces the risk of mpox by 99%.
-
Press releases - 24.07.2024
Fighting leukaemia by targeting its stem cells
Acute myeloid leukaemia is one of the deadliest cancers. Leukaemic stem cells responsible for the disease are highly resistant to treatment. A team from the University of Geneva (UNIGE), University Hospital of Geneva (HUG), and Inserm has made a breakthrough by identifying some of the genetic and energetic characteristics of these stem cells. Notably, a specific iron utilisation process.
-
Press releases - 18.07.2024
A promising new therapeutic approach for patients with arteriovenous malformations
The teams of the translational medicine and targeted therapies unit of the Necker-Enfants Malades AP-HP hospital, Inserm, Paris Cité University within the Necker–Enfants Malades Institute, coordinated by professors Guillaume Canaud (Université Paris Cité, AP-HP) and Laurent Guibaud (Hospices Civils de Lyon, Reference Center for Superficial Vascular Anomalies), conducted a study showing a promising effect of the anticancer drug sotorasib for arteriovenous malformations secondary to a mutation in the G12C type KRAS gene.
-
Press releases - 10.07.2024
A valve made from human collagen opens up new avenues for the treatment of a paediatric heart disease
Researchers from Inserm have developed a pulmonary valve using human collagen. A device that could ultimately be a game-changer in the treatment of paediatric heart diseases, such as tetralogy of Fallot. These findings form part of broader research conducted at BioTis (Inserm/Université de Bordeaux), a tissue bioengineering lab in Bordeaux which develops tissues made from biological material obtained from human cells.
-
Press releases - 05.07.2024
A better understanding of Alzheimer’s disease: A study confirms the utility of caffeine as treatment avenue
In a new study, researchers from Inserm, Lille University Hospital and Université de Lille at the Lille Neuroscience and Cognition research centre have taken a step further in understanding the mechanisms underlying its development. They have shown that the pathological increase in certain receptors in the neurons at the time of disease onset promotes a loss of synapses, and as such the early onset of memory impairments in an animal model of the disease.
-
Press releases - 03.07.2024
Immune cells that protect against post-stroke neurological damage
A team of researchers from Inserm, Caen-Normandy University Hospital and Université de Caen Normandie have looked at the role that immune cells known as central nervous system-associated macrophages (CAMs) could play in the neurological damage that occurs following a stroke. Their research shows that during the course of ageing these cells acquire a key role in regulating the immune response triggered in the wake of a stroke.
-
Press releases - 27.06.2024
Toxoplasmosis: identification of a mechanism ensuring the immune surveillance of infection in the brain
Toxoplasmosis is an infection caused by the parasite Toxoplasma gondii (T. gondii). In over one third of the human population, this parasite establishes a chronic infection of the brain which can have serious consequences in people with compromised immunity. Given the current lack of treatment to eliminate the persistent form of the parasite, a deeper insight into the immune mechanisms controlling this infection is essential if we are to hope to develop new therapeutic strategies. The study, conducted by Inserm researcher Nicolas Blanchard and his team at the Toulouse Institute for Infectious and Inflammatory Diseases (Infinity, Université Toulouse III Paul Sabatier, CNRS, Inserm), has shown that a category of immune cells known as resident CD8+ T cells plays a key role in detecting and neutralising the toxoplasmosis parasite in the brain.
-
Press releases - 21.06.2024
Avoiding kidney transplant rejection using liquid biopsy?
The teams from the kidney transplantation department of Necker-Enfants Malades AP-HP hospital, Inserm and Paris Cité University, as part of the Paris Translational Research Center for Organ Transplantation (PARCC), coordinated by doctor Olivier Aubert and Professor Alexandre Loupy conducted a study on the benefit of liquid biopsy (cfDNA) as a technique for predicting kidney transplant rejection.
-
Press releases - 18.06.2024
Social inequalities widen after a breast cancer
When it comes to health, inequalities can be seen at every level for women with breast cancer: prevention, screening, diagnosis, treatment, and survival. But what about their quality of life? A team from the University of Geneva (UNIGE), the University Hospitals of Geneva (HUG), Inserm, and Gustave Roussy has tracked nearly 6,000 women diagnosed with breast cancer over a 2-year period, showing that socioeconomic status has a major and lasting impact on their quality of life, despite identical medical treatment.